Review article: Non-surgical treatment of hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 1, 2002, Pages 1-15

  Alsowmely, A M ^a   Hodgson, H J F ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALCOHOL; ALKALOID; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; TEGAFUR; URACIL; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ALOPECIA; ARTIFICIAL EMBOLISM; BLOOD TOXICITY; CANCER RISK; COMORBIDITY; CRYOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY; REVIEW; ADJUVANT CHEMOTHERAPY; BRACHYTHERAPY; LIVER TUMOR;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 0036165928     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01149.x     Document Type: Review

References (135)

1. Radiofrequency ablation in the treatment of hepatocellular carcinoma - A clinical viewpoint
2. The management of liver cell cancer
3. The epidemiology of hepatocellular carcinoma
4. The natural history of hepatocellular carcinoma. A study of 100 untreated cases
5. Primary hepatocellular carcinoma
6. Treatment of small hepatocellular carcinoma
7. Liver transplantation. Current status and novel approaches to liver replacement
8. Nonresectional therapies for hepatocellular carcinoma
9. Ethanol injection for treatment of liver tumours
10. Percutaneous ethanol injection therapy for hepatocellular carcinoma: A histopathological study
11. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients
12. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection
13. Tumor size determines the efficacy of percutaneous ethanol injection in the treatment of small hepatocellular carcinoma
14. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation
15. Local ablation therapy for hepatocellular carcinoma
16. Ethanol injection for the treatment of hepatocellular carcinoma
17. Small hepatocellular carcinoma: Treatment with US-guided intratumoral injection of acetic acid
18. Treatment of hepatocellular carcinoma: Too many options
19. Hepatocellular carcinoma
20. Hepatocellular carcinoma
21. Peritoneal seeding of hepatocellular carcinoma after ethanol injection therapy
22. Early diagnosis and treatment of hepatocellular carcinoma
23. North American experience with percutaneous alcohol ablation in 141 patients: Complications and overview
24. Needle tract recurrence of hepatocellular carcinoma after liver transplantation
25. Percutaneous ethanol injection under sonographic guidance of hepatocellular carcinoma in compensated and decompensated cirrhotic patients
26. Treatment of small hepatocellular carcinoma in cirrhotic patient. A cohort study comparing surgical resection and percutaneous ethanol injections
27. Intratumour ethanol injection therapy for solitary minute hepatocellular carcinoma. A study of 37 patients
28. Therapeutic effect of percutaneous ethanol iniection on small hepatocellular carcinoma: Evaluation with CT
29. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: A European experience
30. Percutaneous ethanol injection therapy in 47 cirrhotic patients with hepatocellular carcinoma 5 cm or less: A long-term result
31. Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma or cirrhosis: Long-term results in 268 patients
32. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: A validated prognostic model
33. Small hepatocellular carcinoma: Percutanous alcohol injection - Results in 23 patients
34. No treatment, resection and ethanol injection in hepatocellular carcinoma: A retrospective analysis of survival in 391 patients with cirrhosis
35. Percutaneous ethanol injection of the supplying artery to hepatocellular carcinoma that is not amenable to conventional treatment
36. Cryoablation of liver tumours
37. Hepatic cryotherapy for liver tumors. Development and clinical evaluation of a high-efficiency insulated multineedle probe system for open and laparoscopic use
38. The role of cryosurgery in treatment of hepatic cancer. A report of 113 cases
39. Clinical short term results of radiofrequency ablation in primary and secondary liver tumours
40. Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection
41. New application of ultrasonography: Interventional ultrasound
42. Large-volume tissue ablation with radiofrequency by using a clustered, internally cooled electrode technique: Laboratory and clinical experience in liver metastases
43. Percutaneous US-guided RF tissue ablation of liver metastases: Long-term follow-up
44. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer
45. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma
46. Hepatocellular carcinoma: Radiofrequency ablation of medium and large lesions
47. Increased risk of tumour seeding after radiofrequency thermal ablation for single hepatocellular carcinoma
48. Increased risk of tumour seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma
49. Thermal ablation of liver tumours by radiofrequency, microwave, and laser therapy
50. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma
51. Percutaneous microwave coagulation therapy in liver tumours. A 3-year experience
52. Microwave coagulation therapy for hepatocellular carcinoma
53. Interstitial laser hyperthermia: A new approach to local destruction of turnouts
54. Interstitial laser photocoagulation under ultrasound guidance of liver tumour: Result in 104 treated patients
55. Etiology, screening and treatment of HCC
56. Chemoembolisation of hepatocellular carcinoma
57. Arterial embolisation
58. Hepatocellular carcinoma treated by transcatheter arterial embolisation: Progress evaluation by computed tomography
59. Hepatic artery embolization in 120 patients with unresectable hepatoma
60. Histologic assessment of resected heatocellular carcinoma, after transcatheter hepatic arterial embolisation
61. A 5 year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma
62. Chemoembolization for hepatocellular carcinoma
63. Hepatic artery embolisation and chemoembolisation
64. Transcatheter arterial embolization in unresectable hepatocellular carcinoma
65. Primary treatment of hepatocellular carcinoma by arterial chemoembolization
66. Current treatment modalities for hepatocellular carcinoma
67. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma
68. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial embolisation combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil
69. Effect of repeated transcatheter arterial embolisation on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model
70. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolisation and arterial infusion
71. Five year survival after transcatheter chemoembolisation for hepatocellular carcinoma
72. Analysis of survival in 240 patients with unresectable primary hepatocellular carcinoma treated with hepatic artery chemo-embolization
73. Treatment of hepatocellular carcinoma smaller than 5 cm by transcatheter arterial chemoembolization
74. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence
75. A randomized trial of hepatic chemoembolisation in patients with unresectable HCC
76. Unresectable hepatocellular carcinoma in cirrhosis: Survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization
77. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with child's grade A or B cirrhosis: A multivariate analysis of prognostic factors
78. Prognostic factors for survival following transarterial chemoembolization in advanced hepatocellular carcinoma
79. Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization
80. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma
81. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium
82. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin
83. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization
84. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a Western comparative study in 60 patients
85. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients
86. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
87. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience
88. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival
89. Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma
90. Hepatocellular carcinoma: Outcomes of primary hepatocellular carcinoma treatment: An 8-year experience with 368 patients in Thailand
91. Randomised controlled trials on chemoembolisation for hepatocellular carcinoma. Is there room for new studies
92. Chemotherapy for hepatocellular carcinoma
93. Chemotherapy and radiation therapy
94. 5-Fluorouracil and leucovorin in hepatocellular carcinoma
95. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b
96. Combined doxorubicin and alpha-interferon therapy for advanced HCC
97. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable factors
98. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma
99. Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma
100. A phase 2 study of cisplatin in patients with hepatocellular carcinoma
101. Recombinant interferon-alpha in inoperable hepatocellular carcinoma. A randomized controlled trial
102. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study
103. Complete pathological remission is possible with systemic combination for inoperable hepatocellular carcinoma
104. Randomised controlled trial of inteferon treatment for advanced HCC
105. New guidelines to evaluate the response to treatment in solid tumours
106. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
107. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
108. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable HCC
109. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
110. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma
111. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial
112. Octreotide for cancer of liver and biliary tree
113. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
114. Somatostatin and hepatocellular carcinoma
115. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma
116. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma
117. Powerful radiotherapy for hepatocellular carcinoma
118. Radiation therapy for liver tumours
119. Radiation sensitivity of the liver
120. Radiotherapy
121. Radical radiation therapy for hepatocellular carcinoma
122. Radiotherapy for hepatocellular carcinoma: Clinicopathological study of seven autopsy cases
123. Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma. Experience of Northern California Oncology Group
124. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol
125. Locoregional treatments for hepatocellular carcinoma
126. Iodine 131 antiferritin, a new treatment modality in hepatoma: A radiation therapy oncology group study
127. 90 Yttrium antiferritin: A new therapeutic radiolabeled antibody
128. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer
129. A new, effective and safe therapeutic option using proton irradiation for hepatocellular carcinoma
130. Proton irradiation for hepatocellular carcinoma
131. Adoptive immunotherapy with lymphokine-activated killer cells and recombinant interleukin 2 in patients with unresectable HCC
132. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine activated killer cells generated from autologous spleen cells
133. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced HCC. Comparison between LAK cells and CTL therapy
134. Adoptive immunotherapy to lower postsurgical recurrence rate of HCC. A randomised trial
135. The potential of gene therapy in treatment of hepatocellular carcinoma